Fig. 3From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitisAdverse events experienced by patients in the total cohort and AIT subgroupsBack to article page